Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

271 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-02

Study Completion Date

2017-03-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Assess the efficacy of 2 Cervical Pessaries containing 6.3 g and 7.7 g micronized progesterone for the prevention of preterm delivery, established through spontaneous birth before gestation weeks 32 (31 weeks and 6 days) and 34 (33 weeks and 6 days), when the pessary is inserted during weeks 16th and 24th and removed at 36 weeks and 6 days in pregnant women at high risk of premature birth.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PREGNANT Short Cervix Trial

NCT00615550

Preterm Delivery Short Cervix Short Uterine Cervical Length

COMPLETED PHASE3

Progestagens for the Tertiary Prophylaxis of Preterm Delivery

NCT01178788

Preterm Delivery Neonatal Complications

COMPLETED PHASE3

Vaginal Progesterone for the Prevention of Preterm Birth in Women With Arrested Preterm Labor

NCT01840228

Premature Birth Obstetric Labor, Premature

TERMINATED NA

Comparison in Cervical Length and Prolongation of Gestation Age on Vaginal Progesterone Administration to Pregnant Women After the Acute Phase of Threatened Preterm Birth

NCT06975943

Pregnant Women Pregnancies at Increased Risk of Preterm Birth

ACTIVE_NOT_RECRUITING NA

Cervical Pessary vs Vaginal Progesterone in Preventing Preterm Birth Among Women Presenting With Short Cervix: An Open-label Randomized Controlled Trial

NCT02470676

Preterm Birth Short Cervix

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participant selection will be performed by screening the general population of pregnant women with single fetus monitored by the Hospital Healthcare Network, to investigate by serial transvaginal ultrasound performed between gestation weeks 16 (0 day to 7 days) and 24 (0 day to 7 days) those patients who have a cervical length between 10 mm and 25 mm, and/or women with a single fetus and cervical length ≥10 mm presenting one or more of the following risk factors:

1. preterm birth prior to 35 (34 weeks and 6 days) weeks of gestation;
2. premature rupture of membranes prior to 35 (34 and 6 days) weeks of gestation.

After insertion of the pessary or beginning of the administration with vaginal progesterone capsules and until 28 weeks of gestation, participants in the 3 treatment groups will be monitored every 4 weeks at the most or more often, if the site has established so as a control standard. After 28 weeks, patients should be monitored every 2 weeks.

The proportions of spontaneous preterm delivery before gestation weeks 32 and 34 will be compared between the control group and the 2 groups with the pessaries containing different doses of progesterone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preterm Birth

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Progesterone Cervical Pessary 6.3 g

90 pregnant women with Progesterone Cervical Pessary

Group Type EXPERIMENTAL

Progesterone Cervical Pessary 6.3 g

Intervention Type DRUG

Progesterone Cervical Pessary low dose

Progesterone Cervical Pessary 7.7 g

90 pregnant women with Progesterone Cervical Pessary

Group Type EXPERIMENTAL

Progesterone Cervical Pessary 7.7 g

Intervention Type DRUG

Progesterone Cervical Pessary high dose

Progesterone 200 mg vaginal capsules

90 pregnant women using Progesterone 200 mg vaginal capsules daily

Group Type ACTIVE_COMPARATOR

Progesterone 200 mg vaginal capsules

Intervention Type DRUG

Progesterone 200 mg vaginal capsules daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Progesterone Cervical Pessary 6.3 g

Progesterone Cervical Pessary low dose

Intervention Type DRUG

Progesterone 200 mg vaginal capsules

Progesterone 200 mg vaginal capsules daily

Intervention Type DRUG

Progesterone Cervical Pessary 7.7 g

Progesterone Cervical Pessary high dose

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Hormoral (Trade Mark) Capsules

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women with a single pregnancy and a cervical length of 10 mm - 25 mm between 16 and 24 weeks of gestation, without any previous factors.
* Women with a single pregnancy with 10 mm or more cervical length between 16 and 24 weeks of gestation, and pre-existing risk factors risk factors for preterm birth:
* Previous preterm birth before week 35.
* Previous rupture of membranes before week 35

Exclusion Criteria

* Pregnancies with:

* Major fetal abnormalities, such as lethal malformations or malformations requiring pre- or post-natal surgery; and fetal death before inclusion into the study.
* History of rupture of membranes or prophylactic cerclage before study entry.
* Cervical or vaginal injuries prior to insertion of the pessary (e.g., cervical erosion secondary to trauma, infection, or carcinoma; vesicovaginal or rectovaginal fistulas).
* Unconscious, severely ill or mentally disabled patients, or under 16 years of age.
* Patients for whom use of progesterone is contraindicated.
* Patients with history of thrombosis.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes